Global market valuation was derived through revenue mapping and device deployment analysis. The methodology included:
Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America
Product mapping across automated external defibrillators (AEDs), manual external defibrillators, and wearable cardioverter defibrillators
Analysis of reported and modeled annual revenues specific to external defibrillator portfolios
Coverage of manufacturers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (device deployment volume × ASP by country/setting) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across device types, end-user settings, technology platforms, distribution channels, and usage environments
Data Triangulation & Validation
Research findings were cross-validated through:
Regulatory Database Verification: FDA 510(k) premarket notifications, PMA approvals, and MDR CE marking certifications for device-specific market entry timelines
Clinical Evidence Review: Meta-analyses from Circulation, Resuscitation, and Journal of the American College of Cardiology regarding survival rates and deployment efficacy
Trade Association Corroboration: Data from the Sudden Cardiac Arrest Foundation, Cardiac Arrest Survival Summit reports, and regional resuscitation council statistics
Supply-Demand reconciliation: Cross-referencing manufacturer shipment data with end-user procurement records and public access installation registries